Oragenics has been found out of compliance with NYSE American Equity standards after reporting $3.7 million in stockholders’ equity. It must submit a plan by September 25, 2026, to regain compliance by February 25, 2028; failure could trigger delisting procedures, affecting trading Liquidity and access to equity financing.

Key Highlights

  • Oragenics must submit a compliance plan by September 25, 2026, targeting restored listing eligibility by February 25, 2028.
  • The company recorded net losses in each of its five most recent fiscal years ended December 31, 2025.
  • Delisting could reduce liquidity, limit Equity Financing access and impair the company’s use of employee equity incentives.

Oragenics Inc. (AMEX: OGEN) reported stockholders’ equity of $3.7 million, below the NYSE American requirements tied to its loss history. Its common stock remains listed and traded on the exchange under OGEN with a “.BC” designation indicating below-compliance status.

Compliance Plan Due September 25

Oragenics reported net losses across its five most recent fiscal years ended December 31, 2025, and is not eligible for an exemption from those equity requirements.

The company is preparing a compliance plan for submission by September 25, 2026. The plan must outline milestones, quarterly financial projections and strategic initiatives intended to restore compliance by February 25, 2028.

Listing Continues During Review Period

The shares will continue trading during the plan period if NYSE American accepts the submission, subject to periodic review by exchange staff. The company said it will pursue a transaction or transactions aimed at meeting the exchange’s requirements, while stating that compliance within the required timeframe cannot be assured.

A failure to submit the plan on time, obtain acceptance, make progress consistent with it or meet the standards by February 25, 2028 would expose Oragenics to delisting procedures. The notice does not affect ongoing Business operations or Securities and Exchange Commission reporting requirements.

Delisting could reduce the liquidity and Market Price of the common stock and shrink the pool of investors willing to hold or buy it. It could also hinder equity financing, restrict use of a registration statement for freely tradable securities and impair employee equity incentives.

Peers Moving on This News